In B-cell chronic lymphocytic leukemia (B-CLL) cells, Lyn, a tyrosine kinase belonging to the Src family, is overexpressed and atypically localized in an aberrant cytosolic complex in an active conformation, contributing to the unbalance between cell survival and pro-apoptotic signals. In this study, we demonstrate that Lyn constitutively phosphorylates the immunoreceptor tyrosine inhibitory motifs of the inhibitory cell surface co-receptor CD5, a marker of B-CLL. As a result, CD5 provides an anchoring site to Src homology 2 domain-containing phosphatase 1 (SHP-1), a known negative regulator of hematopoietic cell function, thereby triggering the negative B-cell receptor (BCR) signaling. The subsequent segregation of SHP-1 into two pools, one bound to the inhibitory co-receptor CD5 in an active form, the other in the cytosol in an inhibited conformation, proves crucial for withstanding apoptosis, as shown by the use of phosphotyrosine phosphatase-I-I, a direct inhibitor of SHP-1, or SHP-1 knockdown. These results confirm that Lyn exhibits the unique ability to negatively regulate BCR signaling, in addition to positively regulating effectors downstream of the BCR, and identify SHP-1 as a novel player in the deranged signaling network and as a potential attractive target for new therapeutic strategies in B-CLL.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL), the commonest leukemia in the Western world, is characterized by the clonal expansion of mature, antigen-stimulated CD5 þ B cells with a highly heterogeneous clinical course. 1, 2 The disease mainly results from an anomalous expression of anti-apoptotic molecules 3, 4 as well as peculiar structural and functional features of the B-cell receptor (BCR) related to the presence or absence of somatic mutations of the IgV H (immunoglobulin variable heavy chain) genes, often associated with atypical expression of ZAP-70, and deregulation of signaling pathways downstream of the BCR itself. 5, 6 In normal B lymphocytes, the BCR triggers a set of signaling pathways upon antigen binding, eventually leading to changes in gene expression and determining the cell fate. These events depend on signal duration and intensity as well as on the involvement of co-receptors and intracellular signaling/adaptor proteins that inform B cells of the microenvironmental conditions. [7] [8] [9] Lyn, the tyrosine kinase belonging to the Src family predominantly expressed in B lymphocytes, shares a central role in initiating B-cell signaling, with other Src family kinases (SFKs), such as Fyn and Blk, serving as positive regulator through phosphorylation of the immunoreceptor tyrosine-based activation motifs within the Iga (CD79a) and Igb (CD79b) subunits of the BCR. 10 This phosphorylation promotes the recruitment, and subsequent activation, of Syk to the phosphorylated immunoreceptor tyrosine-based activation motifs via SH2 domains, 11 resulting in the amplification and propagation of the BCR signal through the involvement of numerous molecules, such as phospholipase Cg2 (PLCg2), protein kinase C (PKC) and phosphoinositide 3-kinase and signaling cascades including the ras/mitogen-activated protein kinase pathway. 12, 13 Importantly, Lyn is the only SFK also endowed with the unique ability to phosphorylate immunoreceptor tyrosine inhibitory motifs (ITIMs) in inhibitory cell surface co-receptors such as FcgRIIb1, CD22, CD72 and CD5, and eventually to negatively regulate BCR signaling. 14, 15 Thus, the net effect of Lyn activity results in a fine balance between positive and negative signaling pathways upon BCR engagement.
Several lines of evidence indicate that key molecules of the signaling pathways downstream of BCR engagement in normal B cells, such as Lyn, 16 Syk, 17 PKC, 18 phosphoinositide 3-kinase 19 and mitogen-activated protein kinase p38, 20 are constitutively active in B-CLL cells, resulting in a ligandindependent BCR signaling, also defined tonic signaling. 21 We previously demonstrated that Lyn is overexpressed and atypically localized in the cytosol of B-CLL cells as an integral component of an aberrant cytosolic complex. 22 In this 600 kDa complex, Lyn is found to be in an active conformation and associated with HSP90, this interaction accounting for the altered turnover and the remarkable constitutive activity of Lyn itself. This aberrant complex is disrupted by HSP90 inhibitors (geldanamycin and derivatives), 22 leading to a drop in the aberrant basal protein tyrosine phosphorylation and ultimately inducing B-CLL cells to undergo apoptosis. It has also been demonstrated that apoptosis can be induced by the use of SFK inhibitors (PP2, SU6656 and dasatinib), 17, 23, 24 further strengthening the view that Lyn may represent an attractive target for drug discovery.
The aim of this work was to assess whether the aberrant status of Lyn could affect its ability to target the ITIMs of inhibitory co-receptors in BCR-dependent signaling and whether resistance to apoptosis in B-CLL might reflect an imbalance in Lyn's recognized duplicitous, activatory and inhibitory, function. We herein show that Lyn phosphorylates the disease marker CD5, an inhibitory BCR-associated cell surface co-receptor, which in turn serves as a docking site for Src homology 2 domaincontaining phosphatase 1 (SHP-1). Once recruited to the plasma membrane, SHP-1 is shown to be phosphorylated, and hence activated, by Lyn, consequently causing dephosphorylation of a number of substrates, among which we detected Vav1, the phosphorylation status of which has been recognized to have a key role in modulating apoptotic events. Given that apoptosis occurs when SHP-1 undergoes genetic and pharmacological inhibition, this tyrosine phosphatase can be regarded as a novel potential target for treatment of B-CLL.
Materials and methods

Materials
Anti-IgM-fluorescein isothiocyanate (FITC) and anti-IgD-FITC antibodies were from DakoCytomation (Glostrup, Denmark). Anti-PARP polyclonal antibody was from Roche Applied Science (Mannheim, Germany). Anti-Lyn, anti-Blk, anti-Fyn anti-Mcl-1 (anti-myeloid cell leukemia-1), anti-Vav1, anticalnexin, anti-lamin-B, anti-LDH, anti-aconitase, anti-caspase-3, anti-CD5, anti-CD22, anti-CD72 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-SHP-1, anti-SHP-2, anti-PTP-1B (anti-phosphotyrosine phosphatase), antiSyk, anti-Src, anti-phospho-Src (Tyr416) antibodies were from Millipore (Billerica, MA, USA). Anti-phospho-SHP-1 (Ser591) antibody was from ECM Bioscience (Versailles, KY, USA). Monoclonal CD3-FITC, CD19-FITC, CD5-PE, CD16-PE, CD23-PE, CD38-PE and CD79b-PE antibodies were from BD Biosciences (San Diego, CA, USA). The monoclonal antiphosphotyrosine (clone PY-20) antibody was from BioSource (Invitrogen Corporation, Carlsbad, CA, USA). Anti-b-actin (clone AC-15) and anti-PMCA antibodies, BAY61-3606, MG132 inhibitors, phosphatase inhibitor cocktail 1 (PTP-I) and 2, RPMI-1640 medium were from Sigma-Aldrich (St Louis, MO, USA). MACS separation columns were from Milteny Biotec (Bergisch Gladbach, Germany). SHP-1 inhibitor-I (PTP-I-I), PP2, zVAD-fmk were from Calbiochem-Merck (Darmstadt, Germany). The SHP-1 small interfering RNA (siRNA) and negative control siRNA were from Santa Cruz Biotechnology (catalog number sc-29478). Anti-phospho-SykTyr525/526 antibody was from (Cell Signaling Technology, Danvers, MA, USA). Goat F(ab 0 )2 anti-m was from Southern Biotechnology Associates (Milan, Italy).
Patients, cell separation and culture conditions
After obtaining their informed consent, 40 untreated patients, according to the criteria for diagnosis of B-CLL, 25 were enrolled in the study. Patient characteristics are listed in Table 1 . Peripheral blood mononuclear cells were isolated from the blood of B-CLL patients by density gradient centrifugation through a Ficoll-Hypaque cushion, as previously reported. 26 B cells were isolated as already described. 27 As assessed by flow cytometry, the content of CD19 þ B cells was higher than 95% in all samples.
Untouched peripheral blood B cells were isolated from the peripheral blood mononuclear cells of five healthy donors by negative selection with a B-cell isolation kit and MACS separation columns. The purity of isolated peripheral blood B cells was at least 95% (CD19 þ ), as assessed by flow cytometry. Purified B-CLL cells were either used immediately or cultured (2 Â 10 6 cells/ml) in RPMI-1640 medium supplemented with or without 2% heated-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, at 37 1C in a humidified atmosphere containing 5% CO 2 .
Flow cytometry analysis
The following monoclonal antibodies were used for direct immunofluorescence staining: CD3-FITC, CD19-FITC, anti-IgM-FITC, anti-IgD-FITC, CD5-PE, CD16-PE, CD23-PE, CD38-PE and CD79b-PE. Cells were scored on a FACScalibur analyzer (BD Biosciences, Immunocytometry Systems) and data were processed by CellQuest software (BD).
Cell lysis and subcellular fractionation
For total lysates, normal and B-CLL cells (5 Â 10 5 for each assay) were rapidly lysed in 62 mM Tris/HCL buffer, pH 6.8, 5% glycerol and 0.5% b-mercaptoethanol containing 0.5% sodium dodecyl sulfate.
For subcellular fractionation, B-CLL cells (15 Â 10 6 for each assay) were disrupted on ice by sonication (three cycles of 5 s at 22 Hz at intervals of 15 s) in 350 ml of isotonic buffer (50 mM Tris/ HCl, pH 7.5, 0.25 M sucrose, phosphatase inhibitor cocktail 1 and 2, 1 mM sodium orthovanadate and protease inhibitor cocktail). Homogenates were centrifuged 10 min at 10 000 g, in order to separate the particulate fraction containing nuclei, and other cellular particles (pellet I). The supernatant was further centrifuged 1 h at 105 000 g to separate cytosol from microsomes (pellet II). Protein concentration was determined by the Bradford method.
Treatment of microsomes with lPPase
Microsomes (100 mg) were incubated with 500 U lPPase in phosphatase buffer (50 mM Tris/HCl pH 7.5, 0.1 mM EDTA, 5 mM dithiothreitol, 0.01% BRIJ 35, 2 mM MnCl 2 ) for 45 min at 30 1C, as reported in Trentin et al. 22 Phosphatase activity was stopped by adding phosphatase inhibitor cocktails 1 and 2 and 1 mM sodium orthovanadate. Samples were then subjected to western blot analysis.
Cell viability assay
Cell viability was assessed using the 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) assay. The cells (1 Â 10 6 cell) were placed in 200 ml of media in the presence of various concentrations of PTP-I-I as indicated in each well of a 96-well flat-bottomed microtiter plates in triplicate cultures and incubated 37 1C for different time in an incubator at 5% CO 2 atmosphere. MTT was prepared at 5 mg/ml in phosphatebuffered saline and added to each well (10 ml/100 ml medium) in the assay, and plates were incubated at 37 1C for 4 h. The color development solution was added to each well, and the absorbance was measured at 540 nm wavelength in a multiscan spectrophotometer. The cell viability was expressed as a percentage of absorbance in cells with indicated treatments to that in cells with vehicle control treatment.
Immunoprecipitation
Cells were disrupted on ice by sonication (three cycles of 5 s at 22 Hz intervalled by 15 s) in ipotonic buffer containing 1% NP-40, 20 mM Tris-HCl, pH 7.4, 2 mM EGTA, 150 mM NaCl, a phosphatase inhibitor cocktail 1 and 2, 1 mM sodium orthovanadate and protease inhibitor cocktail. The lysates were centrifuged at 15 000 g for 10 min at 4 1C. The supernatants were immunoprecipitated for 2 h at 4 1C with the appropriate Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al antibodies and immune complexes were recovered by incubation for 1 h with protein A-Sepharose previously saturated with bovine serum albumine. The immunocomplexes were washed three times in 50 mM Tris/HCl (pH 7.5), 0.05% NP-40, 1 mM orthovanadate, phosphatase and protease inhibitor cocktails and subjected to sodium dodecyl sulfate/polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and immunostained with the appropriate antibodies.
Western blotting
Samples, from different cell fractions or immunoprecipitates, were run in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After treatment with 3% bovine serum albumine at 4 1C overnight, membranes were incubated with the appropriate antibodies for 2 h and treated as reported in Gobessi et al. 17 Membranes, when required, were reprobed with other primary antibodies after stripping with 0.1 M glycine (pH 2.5), 0.5 M NaCl, 0.1% Tween 20, 1% b-mercaptoethanol and 0.1% NaN 3 for 2 Â 10 min.
Cell transfection
siRNA transfection into human B-CLL cells was performed using the AMAXA nucleofection system (AMAXA, Cologne, Germany) as described in Ticchioni et al. 28 Briefly, cells (5 Â 10 6 ) were resuspended in 100 ml of Nuclefector Solution, mixed with 300 nM of siRNA duplex (control or against SHP-1), and electroporated using program U-015 on AMAXA nucleofector device. Cells were then transferred to 37 1C preheated medium and incubated for 72 h at 37 1C, 5% CO 2 .
SH2 domain expression
The recombinant GST-SHP-1/SH2 domain was expressed and purified according to the protocol described in Keilhack et al.
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Apoptosis assays
B-CLL cells, incubated for different periods of time with or without PTP-I-I, were collected by centrifugation and washed once with phosphate-buffered saline. Exposure of phosphatidylserine residues was quantified by surface annexin V staining Mutated was defined as having a frequency of mutations 42% from germline VH sequence. c As determined by western blot analysis on purified B cells (purity at least 98%).
Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al using the protocol outlined in the Bender Kit (Bender Medsystems, eBioscience, San Diego, CA, USA). A total of 1 Â 10 6 cells were resuspended in 200 ml of binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl and 5 mM CaCl 2 ) and then incubated with 0.5 mg/ml of annexin V-FITC for 15 min in the dark. Cells were washed again and resuspended in binding buffer. Then 5 ml (20 mg/ml) of propidium iodide (PI) was added to each sample before flow cytometric analysis (FACScalibur analyzer; BD Biosciences, Immunocytometry Systems). Ten thousand cells per sample were acquired with the use of CellQuest software (BD), and data were analyzed by plotting on an annexin V-PI logarithmic scattergram.
Statistical analysis
The bands from immunoblot were quantified by densitometric analysis. Data are presented as mean±s.d. and compared using one-way analysis of variance followed by Bonferroni post hoc test or Student's t-test. A P-value o0.05 was considered as statistically significant. All statistics were performed using GraphPad Prism (version 4) statistical software (GraphPad Software; San Diego, CA, USA).
Results
Subcellular distribution of tyrosine phosphorylation is not related to the tyrosine protein kinase activity in CLL B cells
We had previously demonstrated that the abnormal level of tyrosine phosphorylation in B-CLL cells was accounted for by Lyn, which is the only SFK shown to be overexpressed, constitutively active and abnormally distributed across cell compartments (30% in the cytosol and 60% in microsomes with the same specific activity) as compared with normal B cells (virtually 90% in microsomes, where this kinase is silent unless activated by BCR engagement). 17, 22 This observation led us to further explore whether the aberrant properties of Lyn in leukemia cells could affect the level of tyrosine phosphorylation in the compartments, microsomes and cytosol, where it was detected. Figure 1 shows that tyrosine phosphorylation was remarkably elevated in B-CLL cells compared with normal B lymphocytes, particularly localized to the cytosolic fraction and, albeit to a much lesser extent, to microsomes (II-P) independently of the clinical stage and the prognostic markers, such as mutational status of IgV H and expression of ZAP-70. Moreover, as previously demonstrated, 17 the use of PP2, a specific SFK inhibitor, 30 almost completely abolished the phosphotyrosine signal (data not shown), confirming the role of SFKs in generating it. Since we observed that the level of tyrosine phosphorylation in the compartments examined was not related to the localization of the tyrosine kinases known to be constitutively active in B-CLL cells, Lyn 17 and Syk, 18 we hypothesized that the presence of an active PTP in the II-P could explain this seemingly contradictory finding.
Recruitment of SHP-1 to the plasma membrane is mediated by tyrosine phosphorylation of CD5 via SH2 domain
In addition to taking part in the activation of the BCR cascade, Lyn has a unique negative regulatory function on normal BCR signaling by phosphorylating the ITIMs of BCR-associated co-receptors, thereby inducing the recruitment of negative molecular switches.
14,15 Among these, SHP-1, a cytosolic protein tyrosine phosphatase, binds to phosphorylated ITIMs through two adjacent amino-terminal SH2 domains and dephosphorylates key factors that mediate antigen receptor signaling pathways. 31 
, and in different clinical stages were lysed by sonication in an isotonic buffer and subjected to differential centrifugation to separate nuclei and mitochondria (I particulate fraction, I-P) microsomes (II particulate fraction, II-P) and cytosol. Equal amounts of protein of the different fractions from one normal donor and from CLL patients belonging to three different subsets, UM/ZAP þ (#1 and #20), M-/ZAP À (#11 and #37) and M-/ZAP þ (#12 and #31) were analyzed by immunoblotting with anti-phospho-Tyr (pTyr) antibody and probed with anti-LDH (cytosolic marker), anti-PMCA (plasma membrane marker) and anti-lamin (nuclear marker) antibodies as loading controls. The figure is representative of samples from 6 normal donors and 36 CLL patients belonging to three different subsets UM/ZAP þ , M-/ZAP À and M-/ZAP þ composed of 12 samples each.
Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al previously observed, 33 though differently distributed. In fact, in normal B cells, SHP-1 remained almost exclusively confined to the cytosol, whereas in B-CLL cells, it was found equally partitioned between II-P and cytosol. On the other hand, SHP-2 and PTP-1B non-receptor phosphatases normally present in the cytosol and in the endoplasmic reticulum, respectively, and involved in the signaling cascades that mediate the immune response, 30 ,34 displayed no changes in protein level and localization when comparing normal B lymphocytes with B-CLL cells. These data were confirmed on all the samples examined, 6 from normal donors and all those from 40 B-CLL patients, by western blot analysis of the three tyrosine phosphatases examined and reported in Figure 2b as densitometric units. Though abnormally distributed, SHP-1 was not shown to associate with Lyn, which is overexpressed in B-CLL, 16 either in the cytosol or in the particulate fraction (Figure 2c ). We then attempted to assess whether SHP-1 localized to the II-P via interaction with tyrosine phosphorylated ITIMs of inhibitory Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al co-receptors through its SH2 domains in leukemia cells. By either using the non-specific phosphatase lPPase to dephosphorylate the proteins contained in the II-P fraction or adding the recombinant GST-SHP-1/SH2 domain, potentially capable of competing with SHP-1 for the SH2 anchoring site, we caused a release of SHP-1 from the II-P (P, in Figure 2d ) into the soluble fraction (S, in Figure 2d ), suggesting that the enzyme was recruited in the membrane fraction by means of its SH2 domain. Two lines of evidence prompted us to point to CD5, a cell surface marker of B-CLL, as a factor involved in the recruitment of SHP-1 to the plasma membrane: first, in the normal B-cell subpopulation B1, CD5 is found to be associated with SHP-1 upon tyrosine phosphorylation of the ITIMs of CD5 itself, following BCR engagement, and to negatively regulate BCR signaling; 35, 36 second, CD5 is reported to be constitutively tyrosine phosphorylated in B-CLL. 37 To establish whether SHP-1 was specifically bound to CD5 and/or also to other ITIMcontaining co-receptors in this disease, we immunoprecipitated CD5, CD22 and CD72 from the II-P of B-CLL cells and the immunoprecipitates were probed with anti-pTyr and anti-SHP-1 antibodies, and after stripping with the immunoprecipitating antibody. Figure 3a shows the representative results obtained on the II-P fraction from B-cells from three patients belonging to three different prognostic subsets (left panels), indicating that, although all of the receptors tested were tyrosine phosphorylated, SHP-1 interacted exclusively with CD5. These data were confirmed on all samples examined, nine B-CLL patients for each of the three prognostic subsets patients, by western blot analysis and reported as densitometric units (Figure 3b , right panels). Further confirmation of the specific SHP-1/CD5 Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al interaction was similarly provided by immunoprecipitating SHP-1 and subjecting the immunoprecipitates to western blot analysis with anti-CD5, anti-CD22, anti-CD72 and after stripping with anti-SHP-1 antibody (Figures 3c and d) .
Activation state of SHP-1 in cellular subcompartments of B-CLL cells
To evaluate whether the two pools of SHP-1, the one bound to the plasma membrane via CD5 phosphorylation and the other in the cytosol, reflected a different activation state of the phosphatase, SHP-1 was immunoprecipitated from the two cellular fractions and immunoblotted with antibodies specific for phosphotyrosine and phosphorylated Ser591 (pSer591), which are suggestive of activation or inhibition, respectively, of this phosphatase. 38 SHP-1 proved to be differently phosphorylated in the two subcellular fractions, and namely on tyrosyl residues when isolated from the II-P fraction and on Ser591 when isolated from the cytosol. Figure 4a shows the representative results obtained on the II-P fraction from B-cells from three patients belonging to three different prognostic subsets (left panels). These data were confirmed on all samples examined, nine B-CLL patients for each of the three prognostic subsets, by western blot analysis and reported as densitometric units (Figure 4a , right panels). Figure 4b shows the results obtained on the cytosolic fraction by applying the same approach. Because these data indicate that two pools of SHP-1 were in a different activation state, we used the protein tyrosine phosphatase inhibitor I (PTP-I-I), a SHP-1 inhibitor, to explore whether the tyrosine phosphorylation profile in the two fractions could be affected by downmodulating SHP-1 activity. 39 For this purpose, freshly isolated B-CLL cells from nine B-CLL patients for each of the three prognostic subsets were incubated in the presence of increasing concentrations of PTP-I-I for 20 min, after which II-P and cytosol were isolated and immunoblotted with anti-pTyr antibody. Figure 4c shows that the tyrosine phosphorylation pattern of the cytosol was not changed at any concentration of PTP-I-I compared with the control (right panel, lanes 2-4 vs lane 1), whereas it dramatically increased in a manner dependent on the inhibitor concentration in II P (left panel, lanes 2-4 vs lane 1). This finding was in agreement with the hypothesis that SHP-1 was in an active form in the II-P fraction, accounting for the difference in the phosphorylation level between the II-P fraction and the cytosol in B-CLL cells (Figure 1a) .
To identify the tyrosine kinase responsible for phosphorylating and hence activating SHP-1, freshly isolated B-CLL cells were incubated at different time points in the absence or presence of PP2 or BAY61-3606, specific inhibitors of SFKs and Syk, 40 respectively, the two tyrosine kinase known to be constitutively active in this disease. After such treatment, SHP-1, immunoprecipitated and immunoblotted with anti-pTyr and anti-SHP-1 antibodies, displayed a decrease in tyrosine phosphorylation only when B-CLL cells were treated with PP2, but not with BAY61-3606, suggesting that SFKs, and not Syk, were involved in the activation of the phosphatase (Figure 5a, lower panels) . Likewise, treatment with these inhibitors allowed us to demonstrate that SFKs were also responsible for the constitutive phosphorylation of CD5 (Figure 5a, upper panels) . Results similar to those achieved with PP2 were obtained by employing SU6656, another specific SFK inhibitor (data not shown). To assess which SFK brought about the activation of SHP-1 in B-CLL cells, Lyn, Src, Fyn and Blk, the SFKs more commonly expressed in B cells, were immunoprecipitated from lysates of B-CLL cells at rest or stimulated by BCR crosslinking with antiIgM antibody, and subsequently analyzed by western blot analysis with anti-pTyr416-Src antibody, which recognizes the activated form of SFKs. As shown in Figure 5b , Src, Fyn and Blk were found active only after BCR crosslinking, whereas Lyn was shown to be constitutively active even in resting B-CLL cells, and only weakly modified by stimulation with anti-IgM antibody, as previously demonstrated, 16 indicating that the SFK responsible for the phosphorylation of SHP-1 was Lyn. In addition, the active form of SHP-1 turned out to be scarcely effective in affecting the phosphorylation state of the two constitutively active kinases Lyn and Syk. In fact, as shown in Figure 5c , PTP-I-I left the phosphorylation status of Lyn unchanged and only weakly modified that of Syk (slight increase by 15%), indicating that SHP-1 acts downstream of Lyn, whereas Syk activity is only to a very low extent influenced by SHP-1.
Effect of downmodulation of SHP-1 on the phosphorylation state of Vav1
To confirm the functional role of SHP-1 at the plasma membrane in B-CLL cells, we used the phosphorylation status of Vav1, a member of the Rho/Rac guanine nucleotide exchange factor family and known specific substrate for SHP-1, as a readout of the activation state of SHP-1 itself. 41 Therefore, we attempted to . Under these conditions, the reduced expression of SHP-1 in the particulate fraction was directly proportional to the decrease of the tyrosine phosphorylated, and thus active, form of the phosphatase (Figure 6c, left panel) , whereas the lack of tyrosine phosphorylation in the cytosolic pool of SHP-1 made the significant drop in the expression functionally irrelevant (Figure 6c, right panel) . Furthermore, the reduction of the active form of SHP-1 segregated at the plasma membrane and resulting from SHP-1 knockdown determined effects comparable to those obtained with PTP-I-I on the three substrates taken into account, with an increase in Vav1 phosphorylation and the kinases Lyn and Syk virtually unmodified (Figure 6d ).
The inhibition of SHP-1 induces caspase-independent apoptosis in B-CLL cells
To establish whether SHP-1 is one of the factors directly contributing to the defective apoptosis observed in B-CLL cells, B-CLL cells were incubated in the absence or presence of Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al increasing concentrations of PTP-I-I and the cytotoxic potential of the inhibitor was measured as loss of cell viability (Figure 7a , left panel), obtaining an IC 50 value of 15 mM after 24 h treatment. Subsequently, we monitored the time-dependent effect due to the incubation of B-CLL cells at a concentration of 25 mM PTP-I-I over time, resulting in a dramatic loss of cell viability at 24 h (Figure 7a, right panel) . Figure 7b shows that the cytotoxic effect promoted by PTP-I-I was due to both early (annexin V-positive only) and late (annexin V/PI both positive) apoptosis, but no necrosis concurrently, as revealed by annexin V/PI staining after 24 h of incubation in the absence or presence of 25 mM PTP-I-I.
The apoptosis unleashed by PTP-I-I was characterized by the absence of evidence for the activation of the caspase pathway, as revealed by lack of cleavage of pro-caspase-3, the main effector caspase involved in both intrinsic and extrinsic apoptotic pathways, and PARP-1, a downstream substrate of the caspase cascade, despite the degradation of the antiapoptotic member of the Bcl-2 family termed Mcl-1 (Figure 7) . Mcl-1, overexpressed in a number of hematopoietic cancers, among which B-CLL, with a very short half-life relative to the other Bcl-2 family members and reported to be degraded via both caspase-and proteasome-dependent routes, 42, 43 proved to Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al be downregulated by a proteasome-mediated degradation upon incubation of B-CLL with PTP-I-I, as determined by the use of MG132, a specific and potent proteasome inhibitor (Figure 7d ). These results suggest that in such a caspase-independent apoptotic event, the decrease in Mcl-1 expression might be a consequence of apoptosis and not necessarily a promoting event. Moreover, SHP-1 knockdown, performed on samples from three B-CLL patients for each of the three prognostic subsets, yielded results similar to those described above with a decrease in B-CLL cell viability by 65% after 48 h treatment.
Again, this effect appeared to be due to caspase-independent apoptosis, as suggested by the absence of cleavage of caspase-3 and PARP-1 despite concomitant downmodulation of Mcl-1 ( Figure 8b ).
Discussion
In this study, we identify the tyrosine phosphatase SHP-1 as a novel factor involved in the ligand-independent BCR signaling characterizing B-CLL and exerting an anti-apoptotic function. Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al SHP-1 is predominantly expressed in hematopoietic cells at all stages of maturation and has been implicated in the negative regulation of cell function, in particular contributing to the modulation of B-cell response to antigens and critically to the maintenance of tolerance to self-antigens by mature B cells. 31 The regulation of SHP-1 function is strictly based upon its multimodular structure, containing a central catalytic domain flanked by two SH2 domains at the N-terminus and a C-terminal regulatory tail. 31, 32 The latter region harbors three phosphorylatable sites, Ser591, which is thought to be inhibitory when targeted by PKC, 38 and Tyr536 and Tyr564, the phosphorylation of which by SFKs leads to the activation of the phosphatase. 31 The SH2 domains have been shown to suppress the phosphatase activity when lying within the catalytic cleft, thus producing a steric hindrance to substrate access, [38] [39] [40] which is removed upon engagement of SH2 with phosphorylated ITIMs of cell surface inhibitory co-receptors, 9-12 bringing SHP-1 close to its target molecules. It is to be stressed that Lyn is the only SFK to be responsible for the phosphorylation of ITIMs, thus exhibiting its unique negative regulatory function on BCR signaling, in addition to that of initiating the activatory cascades in normal B cells, which is instead shared by other SFKs. The data presented in this work confirm the dual role of Lyn also in B-CLL cells, where this kinase has also been shown to be aberrantly distributed between plasma membrane and cytosol, 22 and is the only active SFK among those mainly expressed ( Figure 5) ; furthermore, it is responsible for the constitutive phosphorylation of CD5, an inhibitory co-receptor commonly associated with B-CLL, thus providing an anchoring site to the SH2 domains of SHP-1. The pool of SHP-1 bound to the plasma membrane becomes in turn tyrosine phosphorylated, and hence activated, by Lyn itself (Figures 3 and 5) . We demonstrate that CD5 and SHP-1 are Lyn's targets, because the phosphorylation thereof is sensitive to the use of specific SFK inhibitors, such as Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al PP2 and SU6656, and Lyn is shown to be the only SFK responsive to pTyr416-Src antibody, and thus constitutively active ( Figure 5 ). On the other hand, siRNA knockdown proved ineffective in decreasing Lyn protein level, in agreement with our hypothesis that the overexpression of Lyn in B-CLL may depend on a slow turnover due to its association with HSP90 within a cytosolic aberrant multiprotein complex. 22 Interestingly, although other inhibitory co-receptors, such as CD22 and CD72, are found to be tyrosine phosphorylated, hence serving as potential recruitment platforms for SHP-1, as occurs in other cell types, we show here that they are not complexed with SHP-1. Moreover, the partially dephosphorylated status of the plasma membrane in conjunction with the SHP-1/CD5 association suggest that SHP-1 is confined to a selective region of the plasma membrane in B-CLL cells, ultimately exerting its action on a limited subset of substrates. Different is the activation state of SHP-1 in the cytosol, where, despite the large amount of active Lyn, the phosphatase is not phosphorylated at tyrosine residues but at Ser591, which makes it fully inactive. As elsewhere described, Ser591 can be targeted by PKC, 38 which is reported to be upregulated in B-CLL, 18, 40 whereby the Lyn-dependent constitutive activation of Syk has a role in its functional enhancement. 40 In this scenario, the dephosphorylating function of SHP-1 can be viewed as highly specific owing to the direct and indirect involvement of Lyn. In fact, we assume that Lyn constrains SHP-1 to a selective action on the one side by activating SHP-1 recruited to phosphorylated CD5, and on the other by inhibiting the cytosolic pool of SHP-1 through the activation of a hypothetical pathway, which proves to be but still plausible on the basis of earlier findings, and characterized by the axis Lyn-Syk-PKC, which ultimately 'switches off' SHP-1. However, the spatial segregation of the active form of SHP-1 to the plasma membrane could explain the different sensitivity of particulate and cytosol to PTP-I-I, which brings about an increased level of tyrosine phosphorylation only in the former fraction. In this context, SHP-1's action at the plasma membrane appears to be differentiated with respect to the type of substrate, which is exemplified by known targets of SHP-1, such as Syk, Lyn and Vav1 (Figure 6 ), with the former being shown to mediate survival signals in B-CLL cells. 16, 17 We show here that inhibition of SHP-1 by pharmacological (PTP-I-I) and genetic (siRNAs) approaches scarcely, if not at all, affects the phosphorylation status of Syk and Lyn, though resulting in a remarkable increase in Vav1 phosphorylation ( Figure 6 ). This elevation in tyrosine phosphorylation is suggestive of the recognition of Vav1 as a substrate by Syk and SFKs themselves, which are widely known to be implicated in phosphorylating Vav1. This is further confirmed by our results, whereby the treatment with BAY61-3606 and PP2 results in a massive drop in the phosphorylation state of Vav1, thereby leading to the conclusion that dephosphorylation of Vav1 depends on the prevailing action of SHP-1 to the detriment of that of Syk and Lyn. (Figure 6a) . Notably, the function of Vav1, which has a key role in lymphocyte receptor signaling and actin cytoskeletal rearrangement, is influenced by its phosphorylation state. 41, 44 It has been shown that dephosphorylation of Vav1 blocks lymphocyte activation, 45 which underscores the role of the inhibitory signaling pathway mediated by inhibitory co-receptors/SHP-1, and has recently been proposed as a key event inhibiting Fas-induced cell death. 46 In agreement with these data, our results are compatible with the hypothesis that the phosphorylation status of specific protein targets, among which Vav1, determined by the axis Lyn-CD5-SHP-1 may have a role in the maintenance of the leukemic phenotype by counteracting apoptosis, as demonstrated by the substantial drop in cell viability due to the use of PTP-I-I or SHP-1 knockdown. Notably, genetic and pharmacological inhibition of SHP-1 triggers apoptosis through a caspase-independent mechanism despite Mcl-1 downmodulation (Figures 7 and 8) , leaving expression and activity of Lyn and Syk unaltered (Figures 5c and 6d) . In our study, the proteasome-dependent Mcl-1 degradation concomitant with the use of PTP-I-I appears to occur downstream of the caspase-independent apoptotic event rather than being a direct cause thereof (Figure 7d ), at variance with the effects due to Syk inhibition, which instead leads to caspase activation. 17, 40 In conclusion, SHP-1 can be added to the players participating in Lyn-mediated SHP-1 recruitment to CD5 in B-CLL E Tibaldi et al an intricate network of altered signaling pathways characterizing B-CLL, whereby Lyn appears to be critical in directing the action of this phosphatase so as to sustain the survival of leukemia cells, and regarded as a novel potential target, independent of the clinical stage and the prognostic markers characteristic of the clinical course of the disease, for extended therapeutic strategies aimed at breaking the delicate balance underlying the mechanisms of resistance to apoptosis in B-CLL.
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